ArticleCancer management and research2011
Latest developments and emerging treatment options in the management of stomach cancer.
Article in Cancer management and research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.Medicine · 2015Pooled it
- Oncogenic role of LYN in human gastric cancer via the Wnt/β-catenin and AKT/mTOR pathways.Experimental and therapeutic medicine · 2020Article
- The MRTF-A/miR-155/SOX1 pathway mediates gastric cancer migration and invasion.Cancer cell international · 2020Article
- Observational
- miR‑3664‑5P suppresses the proliferation and metastasis of gastric cancer by attenuating the NF‑κB signaling pathway through targeting MTDH.International journal of oncology · 2019Article
- MicroRNA-139 inhibits the proliferation, migration and invasion of gastric cancer cells by directly targeting ρ-associated protein kinase 1.Oncology letters · 2018Article
- Transcriptome profiling of cancer tissues in Chinese patients with gastric cancer by high-throughput sequencing.Oncology letters · 2018Article
- miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells.OncoTargets and therapy · 2016Article
- Surgical interventions for gastric cancer: a review of systematic reviews.International journal of clinical and experimental medicine · 2015Article
- MicroRNA-107 promotes proliferation of gastric cancer cells by targeting cyclin dependent kinase 8.Diagnostic pathology · 2014Article
- miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression.Experimental and therapeutic medicine · 2014Article
- Review
- RNAi-mediated gene silencing of vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of gastric cancer in vivo in mice.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- S-1 (Teysuno®): a review of its use in advanced gastric cancer in non-Asian populations.Drugs · 2013Review
- Metastatic gastric cancer treatment: a little slow but worthy progress.Medical oncology (Northwood, London, England) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer remains a significant health burden worldwide. Most of these malignancies are diagnosed at an advanced stage and are associated with a grim prognosis. Complete removal of macroscopic and microscopic tumor masses along with regional lymphnodes (R0 surgical resection) represents the treatment of choice in localized, nonmetastatic gastric cancer. Chemotherapy, either alone as a perioperative treatment, or in combination with radiation therapy in an adjuvant setting, improves the clinical outcome for patients with resectable tumors. In patients suffering from metastatic disease, chemotherapy and the so-called targeted therapies play a major role in improving survival and quality of life compared with best supportive care. The emergence of new drugs as well as new administration schedules allow physicians to obtain an objective response of up to 60% and, since the utilization of targeted therapies, overall survival has reached 14 months. In order to situate the standard of care and the latest developments in gastric malignancies better, the pertinent English literature, including major Phase III randomized studies and meta-analyses, has been reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.